BioLASCO Taiwan Co. Ltd. (6662) AI Stock Analysis

BioLASCO Taiwan Co. Ltd.

(TPEx:6662)

Select Model

Rating:66Neutral

Price Target:TWD 31.00▲(9.15% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported by a strong balance sheet, continued profitability, and an attractive dividend yield. These strengths are tempered by weaker recent revenue and margin trends, volatile cash generation, and neutral-to-soft technical momentum.

Positive Factors

Stable ProfitabilitySustained gross margins near 39% and a mid-teens net margin show that BioLASCO remains meaningfully profitable across recent periods. This provides an earnings base to support ongoing operations and customer service while offering some resilience as revenue conditions fluctuate.

Negative Factors

Revenue ContractionThe 2025 revenue decline interrupts the prior growth pattern and indicates that demand or customer activity has weakened recently. If the softer top line persists, it could limit operating leverage, reduce reinvestment capacity, and make sustained earnings expansion more difficult.

BioLASCO Taiwan Co. Ltd. (6662) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 727.38M
Dividend Yield: 5.46%
Average Volume (3M): 4,415
Price to Earnings (P/E): 17.8
Beta (1Y): -0.03
Revenue Growth: -8.71%
EPS Growth: -16.08%
Country: TW
Employees: 91
Sector: General
Sector Strength: 55
Industry: Biotechnology

BioLASCO Taiwan Co. Ltd. Business Overview & Revenue Model

Company Description

BioLASCO Taiwan Co., Ltd., established in Taipei in 1990, operates as an international supplier of bio-materials and surgical support services. The company specializes in breeding and producing Specific Pathogen-Free (SPF) laboratory rodents, encompa...

BioLASCO Taiwan Co. Ltd. Financial Statement Overview

Summary

Financial performance is moderate overall: the strong low-leverage balance sheet scored 88, while profitability scored 68 and cash flow scored 58 due to declining revenue, margin compression, and volatile free cash flow.

Income Statement

68Positive

Balance Sheet

88Very Positive

Cash Flow

58Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	258.04M	262.66M	292.50M	264.72M	235.91M	227.58M
Gross Profit	100.51M	101.62M	114.76M	104.35M	104.49M	105.11M
EBITDA	57.67M	59.58M	67.64M	73.86M	59.50M	67.34M
Net Income	40.89M	42.43M	44.03M	49.74M	42.31M	45.15M
Balance Sheet
Total Assets	597.69M	592.58M	612.67M	573.14M	569.69M	574.26M
Cash, Cash Equivalents and Short-Term Investments	141.27M	136.41M	162.52M	201.67M	227.20M	244.47M
Total Debt	87.01M	93.58M	107.01M	58.21M	65.94M	69.18M
Total Liabilities	170.24M	134.86M	163.29M	111.98M	115.05M	113.91M
Stockholders Equity	427.45M	457.72M	449.38M	461.16M	454.64M	460.36M
Cash Flow
Free Cash Flow	33.73M	27.06M	931.00K	27.83M	40.42M	66.49M
Operating Cash Flow	43.89M	48.71M	56.86M	29.46M	44.69M	70.84M
Investing Cash Flow	-8.14M	-20.32M	-97.60M	-8.83M	-28.72M	-13.17M
Financing Cash Flow	-55.79M	-54.50M	4.59M	-46.16M	-48.63M	-57.97M

BioLASCO Taiwan Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6662 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6662	66Neutral	TWD 727.39M	17.75	―	5.46%	-8.71%	-16.08%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

TW:6662 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6662	BioLASCO Taiwan Co. Ltd.	28.40	-1.20	-4.05%
TW:4732	Naturewise Biotech & Medicals Corporation	15.20	-4.90	-24.38%
TW:6572	PlexBio Co., Ltd.	6.28	-3.12	-33.19%
TW:6817	Winston Medical Supply Co., Ltd.	37.50	-60.57	-61.76%
TW:6939	TFBS Bioscience, Inc.	18.90	-4.60	-19.57%
TW:7790	Spirit Scientific Co., Ltd.	39.65	-32.19	-44.80%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

BioLASCO Taiwan Co. Ltd. AI Stock Analysis